ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

This study is currently recruiting participants.
Verified by National Institute on Drug Abuse (NIDA), June 2008

Sponsors and Collaborators: National Institute on Drug Abuse (NIDA)
Thomas Jefferson University
Information provided by: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier: NCT00521248
  Purpose

Neonatal abstinence syndrome is a disease that affects children who were exposed to opioid drugs prior to birth. Commonly used treatments at present include morphine or tincture of opium. Buprenorphine is a drug used in adults to treat narcotic dependence, but has not been used for Neonatal Abstinence Syndrome. This trial is designed to see if the use of sublingual (under the tongue) buprenorphine is able to be used safely and easily in newborns with the neonatal abstinence syndrome. Secondary goals will be to see if treatment with buprenorphine is associated shorter stays in the hospital and fewer days of treatment than the use of standard therapy. Another secondary goal will be to understand buprenorphine concentration in the blood of babies treated with the drug (this is called "pharmacokinetics").


Condition Intervention Phase
Neonatal Abstinence Syndrome
Drug: buprenorphine
Drug: neonatal opium soln.
Phase I

ChemIDplus related topics:   Buprenorphine    Buprenorphine hydrochloride   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Sublingual Buprenorphine safety and tolerability in the neonate [ Time Frame: Index hospitalization ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Buprenorphine Pharmacokinetics [ Time Frame: Index hospitalization ] [ Designated as safety issue: No ]
  • Efficacy: Length of treatment [ Time Frame: Index hospitalization ] [ Designated as safety issue: No ]
  • Efficacy: Length of hospitalization [ Time Frame: Index hospitalization ] [ Designated as safety issue: No ]

Estimated Enrollment:   30
Study Start Date:   April 2004
Estimated Study Completion Date:   August 2009
Estimated Primary Completion Date:   August 2009 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Neonatal opium solution: Active Comparator
Neonatal opium soln.
Drug: neonatal opium soln.
0.4 mg/kg/day morphine every 4 hours
Buprenorphine: Experimental
Sublingual buprenorphine
Drug: buprenorphine
sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • ≥ 37 weeks gestation
  • exposure to opiates in utero
  • demonstration of signs and symptoms of neonatal abstinence syndrome requiring treatment

Exclusion Criteria:

  • major congenital malformations and/or intrauterine growth retardation
  • medical illness requiring intensification of medical therapy
  • concomitant benzodiazepine or severe alcohol abuse, self-report of regular use of alcohol or of benzodiazepines use in the past 30 days, and/or receipt of benzodiazepines by prescription (as determined by self-report or intake urine) by the mother during pregnancy,
  • concomitant use of CYP 3A inhibitors (erythromycin, clarithromycin, ketoconazole, itraconazole, HIV protease inhibitors) or inducers (rifampin, carbamazepine, phenobarbital) prior to initiation of NAS treatment
  • seizure activity or other neurologic abnormality
  • breast feeding
  • inability of mother to give informed consent due to co-morbid psychiatric diagnosis
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00521248

Contacts
Contact: Vidula Damle, MS     215 955 6720     Vidula.damle@jefferson.edu    
Contact: Walter K Kraft, MD, MS     215 955 9077     walter.kraft@jefferson.edu    

Locations
United States, Pennsylvania
Thomas Jefferson University Hospital     Recruiting
      Philadelphia, Pennsylvania, United States, 19107
      Sub-Investigator: Michelle Ehrlich, MD            
      Sub-Investigator: Eric Gibson, MD            
      Sub-Investigator: Jay S Greenspan, MD, MBA            
      Sub-Investigator: Karol Kaltenbach, PhD            
      Sub-Investigator: Kevin Dysart, MD            

Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Thomas Jefferson University

Investigators
Principal Investigator:     Walter K Kraft, MD, MS     Thomas Jefferson University    
  More Information

Responsible Party:   NIDA ( Steve Oversby )
Study ID Numbers:   R21 DA018207-01
First Received:   August 23, 2007
Last Updated:   June 27, 2008
ClinicalTrials.gov Identifier:   NCT00521248
Health Authority:   United States: Food and Drug Administration

Keywords provided by National Institute on Drug Abuse (NIDA):
Neonatal Abstinence Syndrome  
buprenorphine  
neonatal  
opioid withdrawal  

Study placed in the following topic categories:
Morphine
Buprenorphine
Mental Disorders
Neonatal Abstinence Syndrome
Substance-Related Disorders
Disorders of Environmental Origin
Infant, Newborn, Diseases

Additional relevant MeSH terms:
Disease
Physiological Effects of Drugs
Narcotic Antagonists
Central Nervous System Depressants
Narcotics
Pharmacologic Actions
Pathologic Processes
Sensory System Agents
Syndrome
Therapeutic Uses
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on September 05, 2008




Links to all studies - primarily for crawlers